About Parmax Pharma Limited
Data last updated: 11 January 2026
Parmax Pharma Limited is a public limited company based in Hadamtala, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 02 November 1994, the company has been in operation for over 32 years.
Registered with ROC Ahmedabad under CIN L24231GJ1994PLC023504. Listed on BSE: 540359.
Capital: an authorised share capital of ₹6 Cr and a paid-up capital of ₹3.74 Cr. It is led by directors including Ami Shah Rajeshbhai and Nikhil Sureshchandra Uchat.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Plot No. 20 Survey No. 52 Rajkot – Gondal National Highway No. 27, Hadamtala, Gujarat, India – 360311.
As per the financials filed for FY 2025, the company reported a revenue of ₹28.24 Cr, reflecting significant growth compared to the previous year.
The company has a workforce of approximately 9 employees as per the latest available data.
The company is associated with 1 brand - Parmax Pharma. As per MCA filings, the company has open charges of ₹8.4 Cr and satisfied charges of ₹14.96 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website parmaxpharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressPlot No. 20 Survey No. 52 Rajkot – Gondal National Highway No. 27, Hadamtala, Gujarat, India – 360311
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Parmax Pharma Limited
Parmax Pharma Limited operates one associated brand: Parmax Pharma. These brands represent Parmax Pharma Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Parmax Pharma Ltd is a pharmaceutical company that manufactures and sells bulk drugs, drugs intermediates, and specialty chemicals, with a focus on leveraging its scientific expertise and strong manufacturing capabilities to drive growth and profitability. | parmaxpharma.com |
Competitors & Alternatives of Parmax Pharma Limited
Brands and companies operating in the same space as Parmax Pharma Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Hikal
|
APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
Snapdragon Chemistry
|
Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Business Activity of Parmax Pharma Limited
Parmax Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Parmax Pharma Limited
Parmax Pharma Limited is audited by B A SHAH S R MEHTA AND CO (ICAI peer reviewed, certificate valid till 2027-05-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| B A SHAH S R MEHTA AND CO (ICAI peer reviewed, certificate valid till 2027-05-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Parmax Pharma Limited
Parmax Pharma Limited is currently managed by 5 directors, with 17 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ami Shah Rajeshbhai | Director | 17 Jun 2018 | 8 Years 0 Months | Current |
| Nikhil Sureshchandra Uchat | Director | 25 Apr 2023 | 3 Years 2 Months | Current |
|
Umang Alkesh Gosalia
Also directs:
Malwin Pharma Private Limited
|
Managing Director | 02 Jan 2016 | 10 Years 6 Months | Current |
Financials of Parmax Pharma Limited FY 2026 filings available
Parmax Pharma Limited reported revenue of ₹12.11 Cr (down 57.06% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹12.11 Cr | ₹28.2 Cr | ₹11.05 Cr | ₹15.42 Cr | ₹18.25 Cr | ₹26.2 Cr | ₹20.93 Cr | ₹12.01 Cr |
| Other Income | ₹4.68 Lakh | ₹3.96 Lakh | ₹4.81 Lakh | ₹3.97 Lakh | ₹6.28 Lakh | ₹8.89 Lakh | ₹9.78 Lakh | ₹4.82 Lakh |
| Total Income | ₹12.16 Cr | ₹28.24 Cr | ₹11.1 Cr | ₹15.46 Cr | ₹18.31 Cr | ₹26.29 Cr | ₹21.03 Cr | - |
| Cost of Materials Consumed | ₹13.06 Cr | ₹21.54 Cr | ₹7.03 Cr | ₹5.51 Cr | ₹6.72 Cr | ₹13.41 Cr | ₹9.79 Cr | ₹3.92 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹3.18 Cr | -₹25,000 | ₹2.3 Lakh | -₹2.1 Lakh | -₹61,000 | ₹2.31 Lakh | ₹1.47 Cr | ₹1.22 Cr |
| Employee Benefit Expense | ₹2.5 Cr | ₹2.99 Cr | ₹2.91 Cr | ₹2.8 Cr | ₹3.46 Cr | ₹3.54 Cr | ₹2.91 Cr | ₹2.08 Cr |
| Finance Costs | ₹1.24 Cr | ₹58.55 Lakh | ₹62.17 Lakh | ₹36.91 Lakh | ₹38.58 Lakh | ₹35.42 Lakh | ₹12.74 Lakh | ₹3.26 Lakh |
| Depreciation & Amortisation | ₹1.01 Cr | ₹1.03 Cr | ₹1.71 Cr | ₹1.88 Cr | ₹1.93 Cr | ₹1.94 Cr | ₹1.01 Cr | - |
| Other Expenses | ₹3.36 Cr | ₹3.43 Cr | ₹4.46 Cr | ₹4.88 Cr | ₹5.52 Cr | ₹5.82 Cr | ₹4.99 Cr | ₹3.68 Cr |
| Total Expenses | ₹18 Cr | ₹29.57 Cr | ₹16.76 Cr | ₹15.42 Cr | ₹18.01 Cr | ₹25.09 Cr | ₹20.3 Cr | ₹11.96 Cr |
| Profit Before Exceptional Items & Tax | -₹5.85 Cr | -₹1.32 Cr | -₹5.66 Cr | ₹4.61 Lakh | ₹30.32 Lakh | ₹1.21 Cr | ₹73.06 Lakh | - |
| Exceptional Items | ₹0 | -₹1.07 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | - |
| Profit Before Tax | -₹5.85 Cr | -₹2.4 Cr | -₹5.66 Cr | ₹4.61 Lakh | ₹30.32 Lakh | ₹1.21 Cr | ₹73.06 Lakh | ₹9.81 Lakh |
| Total Tax Expense | -₹1.69 Cr | -₹30.11 Lakh | ₹9.47 Lakh | ₹15.02 Lakh | ₹16.18 Lakh | ₹45.4 Lakh | ₹30.2 Lakh | ₹1.94 Lakh |
| Net Profit | -₹4.16 Cr | -₹2.09 Cr | -₹5.75 Cr | -₹10.41 Lakh | ₹14.14 Lakh | ₹75.44 Lakh | ₹42.87 Lakh | ₹7.87 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | - |
| Total Comprehensive Income | -₹4.16 Cr | -₹2.09 Cr | -₹5.75 Cr | -₹10.41 Lakh | ₹14.14 Lakh | ₹75.44 Lakh | ₹42.87 Lakh | - |
| EBITDA (computed) | -₹3.59 Cr | ₹29.42 Lakh | -₹3.32 Cr | ₹2.29 Cr | ₹2.62 Cr | ₹3.5 Cr | ₹1.87 Cr | - |
| Basic EPS | ₹-11.12 | ₹-5.60 | ₹-15.37 | ₹-0.28 | ₹0.38 | ₹2.02 | ₹1.15 | - |
| Diluted EPS | ₹-11.12 | ₹0.00 | ₹-15.37 | ₹-0.28 | ₹0.38 | ₹2.02 | ₹1.15 | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹28.05 Cr | ₹18.75 Cr | ₹15.33 Cr | ₹17.61 Cr | ₹17.97 Cr | ₹22.73 Cr | ₹21.06 Lakh Cr | ₹19.69 Cr |
| Non-current Assets | ₹11.38 Cr | ₹8.75 Cr | ₹9.56 Cr | ₹10.08 Cr | ₹11.42 Cr | ₹12.39 Cr | ₹11.62 Lakh Cr | ₹10.86 Cr |
| Current Assets | ₹16.68 Cr | ₹10 Cr | ₹5.77 Cr | ₹7.53 Cr | ₹6.56 Cr | ₹10.34 Cr | ₹944,437 Cr | ₹8.83 Cr |
| Property, Plant & Equipment | ₹7.86 Cr | ₹7.97 Cr | ₹9.27 Cr | ₹9.5 Cr | ₹10.44 Cr | ₹10.84 Cr | ₹963,875 Cr | - |
| Inventories | ₹7.85 Cr | ₹3.31 Cr | ₹2.39 Cr | ₹4.31 Cr | ₹2.85 Cr | ₹3.95 Cr | ₹272,386 Cr | ₹3.97 Cr |
| Trade Receivables | ₹3.16 Cr | ₹1.28 Cr | ₹1.82 Cr | ₹62.27 Lakh | ₹67.69 Lakh | ₹1.65 Cr | ₹330,463 Cr | - |
| Cash & Equivalents | ₹64.97 Lakh | ₹9.03 Lakh | ₹5.1 Lakh | ₹40.68 Lakh | ₹1.05 Cr | ₹2.55 Cr | ₹176,749 Cr | ₹1.57 Cr |
| Equity (Net Worth) | -₹6.15 Cr | -₹1.99 Cr | ₹10.53 Lakh | ₹5.86 Cr | ₹5.96 Cr | ₹5.82 Cr | ₹506,399 Cr | - |
| Equity Share Capital | ₹4.45 Cr | ₹4.45 Cr | ₹4.45 Cr | ₹4.45 Cr | ₹4.45 Cr | ₹4.45 Cr | ₹445,115 Cr | - |
| Borrowings (Non-current) | ₹11.52 Cr | ₹7.7 Cr | ₹5.91 Cr | ₹4.48 Cr | ₹4.52 Cr | ₹5.43 Cr | ₹503,354 Cr | - |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | - |
| Total Debt (computed) | ₹11.52 Cr | ₹7.7 Cr | ₹5.91 Cr | ₹4.48 Cr | ₹4.52 Cr | ₹5.43 Cr | ₹503,354 Cr | - |
| Current Liabilities | ₹22.68 Cr | ₹13.04 Cr | ₹9.21 Cr | ₹7.14 Cr | ₹7.31 Cr | ₹11.25 Cr | ₹10.89 Lakh Cr | ₹9.82 Cr |
| Total Liabilities | ₹34.2 Cr | ₹20.74 Cr | ₹15.23 Cr | ₹11.76 Cr | ₹12.01 Cr | ₹16.91 Cr | ₹16 Lakh Cr | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹2.36 Cr | -₹65.62 Lakh | -₹19.62 Lakh | ₹33.31 Lakh | ₹74.93 Lakh |
| Investing Cash Flow | -₹89.99 Lakh | -₹70.14 Lakh | -₹1.59 Cr | -₹93.64 Lakh | -₹1.53 Cr |
| Financing Cash Flow | ₹3.81 Cr | ₹1.4 Cr | ₹1.43 Cr | -₹4.42 Lakh | -₹91 Lakh |
| Capital Expenditure | ₹89.99 Lakh | ₹70.14 Lakh | ₹1.59 Cr | ₹93.64 Lakh | ₹0 |
| Free Cash Flow (computed) | -₹3.26 Cr | -₹1.36 Cr | -₹1.78 Cr | -₹60.33 Lakh | ₹74.93 Lakh |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹55.95 Lakh | ₹3.95 Lakh | -₹35.57 Lakh | -₹64.75 Lakh | -₹1.69 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹3.31 Cr | ₹4.33 Cr | ₹2.53 Cr | ₹1.94 Cr | ₹4.83 Cr | ₹6.28 Cr | ₹9.28 Cr | ₹7.82 Cr |
| Other Income | ₹2.59 Lakh | ₹72,000 | ₹70,000 | ₹67,000 | -₹9.77 Lakh | ₹1.27 Lakh | ₹11.65 Lakh | ₹80,100 |
| Total Income | ₹3.34 Cr | ₹4.33 Cr | ₹2.54 Cr | ₹1.95 Cr | ₹4.73 Cr | ₹6.3 Cr | ₹9.39 Cr | ₹7.82 Cr |
| Cost of Materials Consumed | ₹6.41 Cr | ₹3.13 Cr | ₹2.68 Cr | ₹84.97 Lakh | ₹2.96 Cr | ₹4.97 Cr | ₹7.44 Cr | ₹6.17 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹3.15 Cr | -₹2.85 Lakh | -₹12.26 Lakh | ₹12.26 Lakh | ₹74.82 Lakh | -₹41.07 Lakh | -₹3.15 Lakh | -₹30.86 Lakh |
| Employee Benefit Expense | ₹42.2 Lakh | ₹78.42 Lakh | ₹65.94 Lakh | ₹63.15 Lakh | ₹57.49 Lakh | ₹84.38 Lakh | ₹82.12 Lakh | ₹74.85 Lakh |
| Finance Costs | ₹49.63 Lakh | ₹27.53 Lakh | ₹24 Lakh | ₹28.01 Lakh | ₹23.77 Lakh | ₹10.64 Lakh | ₹12.89 Lakh | ₹11.26 Lakh |
| Depreciation & Amortisation | ₹24.98 Lakh | ₹26.67 Lakh | ₹25.58 Lakh | ₹24.12 Lakh | -₹17.7 Lakh | ₹40.91 Lakh | ₹40.34 Lakh | ₹39.62 Lakh |
| Other Expenses | ₹1.19 Cr | ₹63.95 Lakh | ₹90.55 Lakh | ₹58.84 Lakh | ₹1.11 Cr | ₹77.63 Lakh | ₹85.3 Lakh | ₹68.93 Lakh |
| Total Expenses | ₹5.61 Cr | ₹5.06 Cr | ₹4.62 Cr | ₹2.71 Cr | ₹5.45 Cr | ₹6.69 Cr | ₹9.61 Cr | ₹7.81 Cr |
| Profit Before Exceptional Items & Tax | -₹2.27 Cr | -₹73.2 Lakh | -₹2.08 Cr | -₹76.45 Lakh | -₹72.4 Lakh | -₹39.45 Lakh | -₹21.7 Lakh | ₹1.23 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | -₹1.07 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹2.27 Cr | -₹73.2 Lakh | -₹2.08 Cr | -₹76.45 Lakh | -₹1.8 Cr | -₹39.45 Lakh | -₹21.7 Lakh | ₹1.23 Lakh |
| Total Tax Expense | -₹1.69 Cr | ₹0 | ₹0 | ₹0 | -₹30.11 Lakh | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹58.44 Lakh | -₹73.2 Lakh | -₹2.08 Cr | -₹76.45 Lakh | -₹1.49 Cr | -₹39.45 Lakh | -₹21.7 Lakh | ₹1.23 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹58.44 Lakh | -₹73.2 Lakh | -₹2.08 Cr | -₹76.45 Lakh | -₹1.49 Cr | -₹39.45 Lakh | -₹21.7 Lakh | ₹1.23 Lakh |
| EBITDA (computed) | -₹1.52 Cr | -₹19 Lakh | -₹1.58 Cr | -₹24.32 Lakh | -₹66.33 Lakh | ₹12.1 Lakh | ₹31.52 Lakh | ₹52.12 Lakh |
| Basic EPS | ₹-1.56 | ₹-1.96 | ₹-5.56 | ₹-2.04 | ₹-4.00 | ₹-1.05 | ₹-0.58 | ₹0.03 |
| Diluted EPS | ₹-1.56 | ₹-1.96 | ₹-5.56 | ₹0.00 | ₹0.00 | ₹0.00 | ₹-0.58 | ₹0.03 |
Shareholding Pattern of Parmax Pharma Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 30.80%, retail and other public shareholders hold 69.20% of Parmax Pharma Limited. The company had 2,388 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% |
| Public | 69.20% | 69.20% | 69.20% | 69.20% | 69.20% | 69.20% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 30.80% | 30.80% | 30.83% |
| Public | 69.20% | 69.20% | 69.17% |
| Promoter change (YoY, %pts) | +0.00 | -0.03 | - |
Charges & Borrowings of Parmax Pharma Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Apr 2025 | Others | ₹8.4 Cr | Open |
| 31 May 2023 | Others | ₹6.72 Cr | Satisfied |
| 08 Feb 2019 | Hdfc Bank Limited | ₹1.12 Cr | Satisfied |
| 16 Oct 2018 | Hdfc Bank Limited | ₹6.85 Cr | Satisfied |
| 28 Jul 2017 | Hdfc Bank Limited | ₹26.7 Lakh | Satisfied |
Total charge records: 5 View all charges
Employees and EPFO Compliance at Parmax Pharma Limited
Parmax Pharma Limited has a workforce of 9 employees as of Apr 08, 2024.
Employee Count & EPFO Data of Parmax Pharma Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Parmax Pharma Limited
GSTIN & GST Filing Data of Parmax Pharma Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Parmax Pharma Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Parmax Pharma Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Parmax Pharma Limited
MSME Payment Delays by Parmax Pharma Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Parmax Pharma Limited
Subsidiaries & Group Companies of Parmax Pharma Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Parmax Pharma Limited with ownership details.
MCA Filings & Documents of Parmax Pharma Limited
MCA Filings & Documents of Parmax Pharma Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Parmax Pharma Limited
Frequently Asked Questions about Parmax Pharma Limited
Parmax Pharma Limited is an active public limited company in the pharma sector based in Hadamtala, Gujarat, India. It was incorporated on 02 November 1994 (32+ years old) and is registered under CIN L24231GJ1994PLC023504. Listed on BSE: 540359. The company has 9 employees.
Parmax Pharma Limited reported revenue of ₹28.24 Cr for FY 2025 (up 154.00% YoY).
The current directors of Parmax Pharma Limited are:
- Ami Shah Rajeshbhai
- Bhakti Rameshbhai Aghera
- Nikhil Sureshchandra Uchat
- Keyur Dineshbhai Vora
- Umang Alkesh Gosalia
The primary industry of Parmax Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Parmax Pharma Limited is listed on BSE with code 540359.
Parmax Pharma Limited can be reached at the registered office: Plot No. 20 Survey No. 52 Rajkot – Gondal National Highway No. 27, Hadamtala, Gujarat, India – 360311, or through the website parmaxpharma.com.